Huge Insider Buys at Energy Giants, Bill Ackman Boosts Real Estate Stake Again24/7 Wall Street • 11/14/23
Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 11/13/23
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPTPRNewsWire • 11/05/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTPRNewsWire • 11/03/23
Sarepta Therapeutics Announces Third Quarter 2023 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 11/01/23
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever TestInvestors Business Daily • 10/31/23
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SRPTBusiness Wire • 10/31/23
Sarepta Therapeutics shares plunge as gene therapy trial falls short of primary goalMarket Watch • 10/31/23
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene TherapyInvestors Business Daily • 10/30/23
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular DystrophyBusiness Wire • 10/30/23
Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular DystrophySeeking Alpha • 10/25/23
Sarepta Therapeutics (SRPT) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks Investment Research • 10/25/23